If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
== History == In 1974, a four-year-old tomcat with fragile skin was taken to Cornell University's New York State Veterinary College Small Animal Clinic for investigation. Dr DV Scott noted that its skin was exceptionally thin and velvety in texture. It was hyperextensible (extremely stretchy) and had a criss-cross network of fine white scars from previously healed tears. When fur was clipped from a foreleg to gain a blood sample, the skin peeled away. Peeling was found to occur whenever the slightest pressure was applied anywhere to the cat's skin. Investigation showed that the collagen fibres in the cat's skin were abnormal. In 1975, an adult female cat examined by W.F. Butler of Bristol University's Anatomy Department was found to have very fragile skin on its body. It had abnormally low levels of collagen in the skin of its lower back. In 1977, Drs. Donald F. Patterson and Ronald R. Minor of the university of Pennsylvania's School of Veterinary Medicine studied a young short-haired gray tomcat which had severely lacerated its skin through normal scratching. Its skin was found to be delicate and easily torn. It was also abnormally elastic, and the skin of the back could be extended to a distance above the backbone equal to about 22% of the cat's entire body length. They wrote a paper on the subject and included photos of the cat with its skin gently stretched into "wings". Because of the difficulties in caring for a cat with an incurable skin fragility problem, they donated it to the veterinary school.
Chondronectin is a high molecular weight collagen matrix protein (~180 kDa), or also known as a glycoprotein, and is most commonly found in human synovial fluid. It is mainly responsible for binding chondrocytes and collagen II substrates together in the extracellular matrix (ECM). Chondronectin is characterized as a trimeric protein, that is linked with disulfide bonds. It also has been noted to appear compact and globular in nature. Chondronectin is responsible for helping anchor chondrocytes, bearing mechanical forces and even maintaining homeostasis on a physiological level. Chondronectin works within tissue, where it joins other proteins to build a strong but flexible framework. This structure helps keep joints stable during movement and repeated pressure. Without adhesive matrix proteins like chondronectin, cartilage tissue would have a harder time handling everyday mechanical stress. Chondronectin acts as a strong binding protein inside the body's joints. It helps attach important cartilage cells directly to tough collagen fibers. These cells main responsibility is maintaining healthy cartilage tissue. This protein helps the surrounding tissue structure stay firm and stable while keeping the cartilage properly organized. Without this important connection, the framework of the joins could gradually lose stability. The protein has a three part molecular shape that helps keep it structurally stable. It remains strong while interacting with nearby matrix tissues and surrounding support components.
24294Pu + 2210Ne → 264−x104Rf → 264−x104RfCl4 The researchers considered the results to support the 0.3 second half-life. Although it is now known that there is no isotope of element 104 with such a half-life, the chemistry does fit that of element 104, as chloride volatility is much greater in group 4 than in group 3 (or the actinides). In 1969, researchers at University of California, Berkeley conclusively synthesized the element by bombarding a 249Cf target with 12C ions and measured the alpha decay of 257Rf, correlated with the daughter decay of 253No:
The primary purpose of freeze drying within the food industry is to extend the shelf-life of the food while maintaining the quality. Freeze-drying is known to result in the highest quality of solid foods of all drying techniques because structural integrity is maintained along with preservation of flavors. Because freeze drying is expensive, it is used mainly with high-value products. Examples of high-value freeze-dried products are seasonal fruits and vegetables because of their limited availability, and foods used for military rations, astronauts/cosmonauts, and/or hikers. Water-based drinks such as coffee and tea are also freeze-dried. Compared to heat-based drying, freeze-drying preserves more volatile aroma compounds. Freeze-drying is also used to make instant soup bricks. It can also preserve raw ingredients such as egg whites for baking.
=== Abuse of migrants === According to Human Rights Watch, Houthi militias have "beaten, raped, and tortured detained migrants and asylum seekers from the Horn of Africa." UN experts have warned that female migrants face sexual violence, forced labor, and forced drug trafficking by smugglers who collaborate with the Houthi-controlled Yemen Immigration, Passport and Nationality Authority (IPNA).
Sources: en.wikipedia.org
=== Bleeding time === Bleeding time was developed as a test of platelet function by Duke in 1910. Duke's test measured the time taken for bleeding to stop from a standardized wound in the ear lobe that was blotted every 30 seconds, considering less than 3 minutes as normal. Bleeding time has low sensitivity and specificity for mild to moderate platelet disorders and is no longer recommended for screening.
urged Ukrainians to remain within the Soviet Union, calling the choice between backing Gorbachev and backing independence movements a "false choice" and pledged to maintain "the strongest possible relationship" with Gorbachev's government. Ukrainians ignored him within months, voting overwhelmingly for independence that December—not, per Judt, from any sudden patriotic awakening, but because independence had become a matter of self-preservation rather than self-determination. The episode undercuts the self-congratulatory narrative that later entered the American public record; Washington did not bring communism down inasmuch as it simply watched it implode on its own schedule. In an attempt to halt the rapid changes to the system, a group of Soviet hardliners represented by Vice President Gennady Yanayev launched a coup against Gorbachev in August 1991. Yeltsin's response did more to decide the coup's outcome than any single military calculation: emboldened by a personal meeting with Bush just three weeks earlier, he denounced the takeover as an illegal coup d'état from the Russian parliament building, directed the resistance from its steps, and conducted a running set of negotiations with world leaders before the assembled international press—all but one of whom withheld recognition from the plotters.
The Trump administration has repeatedly deployed federal forces, including active-duty military personnel and federalised National Guard forces, into certain U.S. cities. Trump has given multiple explanations for the deployments, saying they are part of crackdowns on protests, civil unrest, crime, homelessness, and illegal immigration. The actions targeted Democratic Party-led cities and sparked significant controversy, with critics labeling them as abuses of power and potential violations of laws like the Posse Comitatus Act, which limits military involvement in domestic law enforcement. The moves came amidst broader expansions of the military's domestic use during the second Trump administration, and Trump's prior comments during his presidential campaign to use the military to end civil unrest and protests without consent from state governors and target "the enemy within".During the June 2025 Los Angeles protests against local immigration raids, Trump federalized the California National Guard and deployed them to Los Angeles along with 700 Marines under Joint Task Force 51. Declaring a crime emergency in August 2025, the Trump administration deployed 2,000 National Guard soldiers to Washington, D.C. In September 2025, Trump announced the deployment of 150 unarmed national guardsmen to Memphis, Tennessee, saying that the city "is deeply troubled". Their presence in Memphis started on October 1.
There were concerns in the 2000s about the sugar and vitamin content of Ribena, a blackcurrant-based syrup and soft drink owned by GSK until 2013. Produced in England by H.W. Carter & Co from the 1930s, the company's unbranded syrup was distributed to children as a source of vitamin C during World War II, which gave the drink a reputation as good for health. Beecham bought H. W. Carter in 1955. In 2001, the British Advertising Standards Authority (ASA) required GSK to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay. A company poster showed bottles of Toothkind in place of the bristles on a toothbrush. The ASA's ruling was upheld by the High Court. In 2007, GSK was fined US$217,000 in New Zealand over its claim that ready-to-drink Ribena contained high levels of vitamin C, after two schoolgirls showed it contained no detectable vitamin C. In 2013, GSK sold Ribena and another drink, Lucozade, to the Japanese multinational Suntory for £1.35 billion.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.